Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Pfizer Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.04 (market cap $44.49B), while Pfizer Inc trades at $28.01 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 3.6× JPMorgan Nasdaq Equity Premium Income ETF's market cap, and Pfizer Inc pays a 6.18% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 65 Days and Pfizer Inc for 158 Days on average.
| JEPQ | PFE | |
|---|---|---|
Market Cap | $44.49B | $158.56B |
Volume | 5,681,789 | 44,138,282 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $29.02 |
52-Week Low | $53.77 | $23.67 |
Typical Hold Time | 65 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.03, down 0.39% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF maintains strong income generation through its covered-call strategy, with recent dividends ranging from $0.57 to $0.70 per share. Financial media coverage highlights JEPQ's 11% estimated annualized yield and suitability for retirement income, though analysts note the trade-off between high current income and limited price appreciation potential.
JEPQ offers exceptional current income for investors seeking monthly cash flow, with its covered-call strategy performing well in volatile markets. However, the ETF faces risks from market volatility dependence and potential principal erosion if yield chasing outweighs total return considerations. Institutional interest remains strong, with Envestnet increasing its position by 8.2% recently.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
